<p>Parkinson's disease (PD) is a neurodegenerative disorder that primarily impinges the dopaminergic neurons in a particular region of Brain termed as Substantia Nigra. The disease affects more than 1900 people per 100,000 aged 80 years and above. Furthermore, men are 1.5 times more prone than their counterpart. Potential biomarkers escalated the precise diagnosis and helped to initiate treatment to limit its adversity. The current therapeutic schemes are focused on administration of Dopamine precursor, Dopamine agonist, Monoamine oxidase (MAO) inhibitor, Catechol-o-methyl transferase (COMT) inhibitors and deep brain stimulation. The CNS delivery focuses mainly on increasing the dopamine level in the brain. CNS drug delivery faces a crucial challenge of crossing Blood Brain Barrier. Blood-Brain Barrier Penetration can be attained by several techniques. Conventional drug therapy yields harmful affects to the patients without much therapeutics. It is visible that crossing BBB is quite strenuous process. It is mandatory for developing a novel approach untangling these situations. Nanotechnology-based formulations like nanosuspensions, nanotubes etc. promotes the penetration of drug across the sophisticated barrier without creating any deterioration to cells or organs. Several novel routes for drug administration reduce dose intake with increased and precise pharmacological action. Nanoformulations and Novel routes of drug administration are a promising tool to enhance the action of drug which helps to abate the symptoms of the Disease and assist in the betterment in treatment. © 2018 Pharmascope Publications. All rights reserved.</p>
cited By 0
Sreeja C. Nair, Thayyilakandy, S., Arjun, K. K., Krishnakumar, G., and Gayathri, P. S., “A futuristic perspective in subsiding the symptoms of parkinson’s disease”, International Journal of Research in Pharmaceutical Sciences, vol. 10, pp. 975-989, 2019.